RIPK3 and neoplasm: Accordingly, inhibition of cholesterol synthesis via itraconazole-mediated suppression of the upstream RIPK3-protein kinase B (AKT)-mammalian target of rapamycin complex 1 (mTORC1) pathway enhanced MDSC immunosuppressive activity and increased tumour burden.